No Data
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
OBIO and CATTI Collaborate to Boost Canada's Biomanufacturing Capacity for Advanced Therapies
The first gene therapy CDMO stock cannot break out of the loss "vortex"! HUYA Bio had a net loss of 0.19 billion in the first three quarters.
Hepalink is still deeply in the vortex of losses, with a net loss attributable to the mother of 0.19 billion yuan in the first three quarters of this year, a year-on-year decrease of 166.90%, compared to a net loss of 71.0996 million yuan in the same period last year. Hepalink revealed that customers are more price-sensitive due to lack of financing, and prices of different types of CDMO orders are at historically low levels.
Heyuan Biotech: Report for the third quarter of 2024
Third Quarter Report 2024
Hugestone Biotech (688238.SH) released its performance for the first three quarters, with a net loss of 0.19 billion yuan.
Hengyuan Biology (688238.SH) released the third quarter report for 2024, during the reporting period the company achieved revenue...
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?No Data
No Data
